--- title: "Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273233427.md" description: "Johnson & Johnson reported Q4 2025 adjusted earnings of $2.46 per share, exceeding estimates, with sales of $24.56 billion, up 9.1% year-over-year. The company anticipates 2026 sales to reach $99.50-$100.5 billion, surpassing consensus expectations. Key growth drivers included oncology and MedTech products, while immunology sales declined. Shares are near a 52-week high, trading at $216.24, down 0.90% in premarket." datetime: "2026-01-21T12:56:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273233427.md) - [en](https://longbridge.com/en/news/273233427.md) - [zh-HK](https://longbridge.com/zh-HK/news/273233427.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273233427.md) | [繁體中文](https://longbridge.com/zh-HK/news/273233427.md) # Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion **Johnson & Johnson** (NYSE:JNJ) on Wednesday reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44. The pharmaceutical and medtech giant reported sales of $24.56 billion, up 9.1% year over year and beating the consensus of $24.16 billion. Operational growth was 7.1%, and adjusted operational growth was 6.1%. Innovative Medicine sales increased 10% or 7.9% operationally to $15.76 billion. Fiscal 2025 sales increased 6% to $60.40 billion. 2025 operational sales grew 5.3%, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to Caplyta. Growth was driven primarily by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), and Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, and Spravato (esketamine) in neuroscience. Growth was partially offset by an approximate (1,040) basis points impact from Stelara in Immunology. Cancer drug sales increased to $6.86 billion, up 24.8% (+21.9% operational). Immunology sales declined to $3.86 billion, a 8.9% decrease (or 10.3% on an operational basis). MedTech sales increased 7.5% to $8.80 billion. 2025 operational sales grew 5.4%, with net acquisitions and divestitures positively impacting growth by 1.1% primarily due to Shockwave. Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, and wound closure products in General Surgery. Johnson & Johnson, in its earnings presentation, highlighted that its cancer cell therapy Carvykti and Shockwave each generated annual sales of over $1 billion. The company said it has 28 platforms with at least $1 billion in annual revenues. ## Outlook Johnson & Johnson issued fiscal 2026 adjusted earnings guidance of $11.43-$11.63, compared to the consensus of $11.45. The company expects 2026 sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion. **Price Action:** Johnson & Johnson shares were down 0.90% at $216.24 during premarket trading on Wednesday. The stock is trading near its 52-week high of $220.11, according to Benzinga Pro data. _Photo by Tada Images via Shutterstock_ ### 相关股票 - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [Johnson & Johnson (JNJ.US)](https://longbridge.com/zh-CN/quote/JNJ.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) ## 相关资讯与研究 - [Bourgeon Capital Management LLC Purchases 5,000 Shares of Johnson & Johnson $JNJ](https://longbridge.com/zh-CN/news/281678278.md) - [Daratumumab becomes first oncology injectable approved for patient administration](https://longbridge.com/zh-CN/news/280990101.md) - [Orser Capital Management LLC Purchases Shares of 5,217 Johnson & Johnson $JNJ](https://longbridge.com/zh-CN/news/280872064.md) - [Nanobiotix Lung Cancer Trial Data Support Re Rating And Key Catalysts](https://longbridge.com/zh-CN/news/281200344.md) - [Royalty Pharma Leans Into R&D And AI To Shape Future Royalties](https://longbridge.com/zh-CN/news/281693786.md)